We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

JSTL:BSEJeevan Scientific Technology Ltd Analysis

Data as of 2026-05-18 - not real-time

₹81.74

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Jeevan Scientific Technology Limited is trading at ₹81.74, comfortably above the 20‑day SMA (≈₹83.17) but below the 50‑day SMA (≈₹73.05), indicating a short‑term bullish bias. The RSI sits at 53, suggesting neutral momentum, while the MACD shows a bearish crossover (line ≈ 3.21 vs signal ≈ 3.94) and a negative histogram, warning of potential downside pressure. Price is near the identified support of ₹75.61 and well below the resistance of ₹93.90, with volume trending downward, which could limit upside momentum. Volatility is high at over 52% 30‑day and beta is very low (≈0.12), implying the stock moves sharply on its own rather than with the market. On the fundamentals side, revenue surged 52.5% YoY and gross margins are exceptional (~90%), yet the company posted a –3.7% profit margin, negative EPS (‑1.28) and carries a large debt load (≈₹249 M) with a debt‑to‑equity of 52.8, making earnings sustainability a concern. The price‑to‑book of 2.72 and price‑to‑sales of 3.24 suggest the market is pricing in growth expectations despite the lack of profitability, while the Fear‑Greed Index at 87.16 signals extreme greed in the broader market.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Price hovering just above key support at ₹75.61
  • Bearish MACD crossover and negative histogram
  • Decreasing volume and high short‑term volatility

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • Strong revenue growth (52.5% YoY) and high gross margins
  • Continued net losses and elevated debt‑to‑equity ratio
  • Neutral momentum indicators (RSI ~53, bullish trend direction)

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Expanding biotech services market in India
  • Robust top‑line growth and potential to improve profitability
  • Current valuation reflects growth expectations despite earnings gaps

Key Metrics & Analysis

Financial Health

Revenue Growth52.50%
Profit Margin-3.74%
Debt/Equity52.79
P/B Ratio2.7
Industry P/E26.7

Technical Analysis

TrendBullish
RSI53.0
Support₹75.61
Resistance₹93.90
MA 20₹83.17
MA 50₹73.05
MA 200₹59.30
MACDBearish
VolumeDecreasing
Fear & Greed Index87.16

Valuation

GradeOvervalued
TypeGrowth

Risk Assessment

Beta0.12
Volatility52.76%
Sector RiskHigh
Reg. RiskHigh
Geo RiskMedium
Currency RiskMedium
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.